Can Evolent Health (EVH) Stock Reach $5.75?

Key Takeaways

• The central $5.75 target is the arithmetic mean of roughly 14 current analyst price targets for Evolent Health, Inc. (EVH), a value-based specialty care company.
• With the stock near $4.33, reaching $5.75 would require an upside of roughly 33%, a substantial move from current levels.
• Individual analyst targets span a wide range, from a low of $3.00 to a high of $8.00, reflecting sharply divided views on the company's turnaround.
• Bullish analysts point to accelerating revenue, raised 2026 guidance, and a large oncology partnership; cautious analysts emphasize persistent net losses and high leverage.
• Key risks include Medicaid and exchange membership declines, elevated net debt, and uncertainty around the timeline to durable profitability.
• For more on EVH's Major News, Today's Price Move, Forecast, and Earnings, explore the additional Tickeron pages dedicated to this ticker.
• Explore Trending AI Robots to see how AI-driven trading tools are monitoring opportunities across thousands of stocks and ETFs.

Analyst Price Targets and Consensus View

The central $5.75 stock price target reflects an average of roughly 14 analyst price targets, with individual estimates ranging from $3.00 to $8.00. Recent individual targets cluster near $6.00: J.P. Morgan (Overweight) and TD Cowen (Buy) each raised their targets to $6 from $5 in August 2026, while Citi upgraded the stock to Buy with a $6 target, and Canaccord, Truist, and Oppenheimer also carry $6 targets. UBS holds a $5 target, while RBC Capital is the most cautious at $3 with a Hold rating.

The spread between $3 and $8 underscores how differently analysts see the risk-reward. Bulls emphasize reaccelerating revenue, the Performance Suite, and an expanded oncology contract pipeline; bears and Hold-rated analysts focus on sustained net losses, high net leverage, and membership pressures. The average analyst rating remains "Buy," but a meaningful minority of analysts are on the sidelines.

Current Market Position and Path Toward the Target

With Evolent Health shares near $4.33, the move to $5.75 implies roughly 33% upside, a substantial advance. The company reported second-quarter 2026 revenue of about $652.5 million, ahead of the roughly $599.8 million consensus, and raised its full-year 2026 revenue outlook to a range of $2.6 billion to $2.7 billion while tightening adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) guidance to $120 million to $135 million.

The path to the target depends on whether management can sustain growth while closing the gap toward profitability. Analysts modeling the year expect roughly 40% revenue growth in 2026 and about 25% in 2027, driven by Performance Suite adoption and new client launches. However, the stock's 52-week range of roughly $2.10 to $7.66 illustrates how volatile the shares have been as investors weigh growth against ongoing losses.

What Could Support a Move Toward the Target

• Reaccelerating revenue, with second-quarter growth and a raised 2026 outlook signaling renewed commercial momentum.
• A large multi-state oncology partnership that could broaden covered membership and diversify the customer base.
• AI-driven authorization automation ("Auth Intelligence") aimed at reducing manual work and improving margins over time.
• Analyst revisions skewing positive, including target increases at J.P. Morgan and TD Cowen and a Citi upgrade to Buy.
• Management's expectation of more than 25% revenue growth in 2027, supporting the scale argument behind the higher targets.

What Could Prevent the Target From Being Reached

• Persistent net losses, with the company yet to convert rapid revenue growth into durable profitability.
• High net leverage, which limits financial flexibility and raises refinancing and interest-burden risk.
• Expected Medicaid contraction and exchange pressures that could reduce covered membership and weigh on 2027 growth.
• Valuation and sentiment risk in the healthcare services sector, which has seen sharp repricing during periods of policy uncertainty.
• Execution risk around large client launches and the timing of adjusted EBITDA recognition.

Technical Levels and Market Structure

Evolent Health's long-term structure reflects a deep drawdown followed by a partial recovery. The shares trade near $4.33, well off a 52-week high around $7.66 and above a 52-week low near $2.10. The $5 level stands out as a psychological round-number resistance zone, with the $5.75 target sitting just above it; the low end of the analyst range near $3.00 marks a notable support reference on the downside.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of roughly 12 months, though individual analysts apply different assumptions about margins and membership. Near-term catalysts include the third-quarter 2026 earnings report scheduled for November 5, 2026, subsequent guidance updates, and any revisions from analysts as new contract and membership data emerge. Investors should also watch adjusted EBITDA trends, net leverage, and any updates on the oncology partnership and client launches.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot changing trends more efficiently than by manually scanning charts. For investors tracking EVH alongside the broader market, this tool can add a data-driven layer to the decision-making process.

Final Assessment

The $5.75 central target for Evolent Health represents the average of roughly 14 analyst price targets and implies about 33% upside from a price near $4.33. The case for reaching it rests on reaccelerating revenue, a raised 2026 outlook, and a growing specialty-care contract pipeline, while the case against it centers on persistent losses, high leverage, and membership headwinds. The wide $3.00-to-$8.00 analyst range shows genuine disagreement about the company's trajectory, and investors should weigh both the growth narrative and the profitability risks, watching upcoming earnings, guidance, and analyst revisions rather than treating the average as a guaranteed outcome.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations